Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Immunovant Inc. Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Immunovant Inc. Common Stock trades at $27.97 (market cap $5.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 5.2× Immunovant Inc. Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals.
| GEHC | IMVT | |
|---|---|---|
Market Cap | $31.07B | $5.93B |
Volume | 3,443,020 | 1,242,632 |
Sector | Health | Health |
52-Week High | $88.16 | $44.96 |
52-Week Low | $59.48 | $17.41 |
Enterprise Value | $39.53B | $5.03B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 6 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Immunovant (IMVT) trades at $28.71, down 2.61% with bearish technical signals despite strong analyst support. The company shows no revenue with substantial losses (-$413.84M net income) and negative margins, though it maintains a robust cash position from recent financing. Recent clinical setbacks, including the discontinuation of IMVT-1402 for cutaneous lupus, have pressured the stock, while multiple law firm investigations into potential fiduciary breaches add uncertainty.
The investment case hinges on IMVT-1402's success in other indications like Graves' disease, with a bullish analyst consensus (78% buy ratings) contrasting high execution risks. Key risks include clinical trial outcomes, cash burn, and legal overhangs. The stock's viability depends heavily on pipeline progress against a backdrop of persistent losses and volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
